文献速递临床试验与 GCP流行病学与生物统计

4%四钠EDTA封管液预防中心静脉通路装置相关并发症:一项随机临床试验

4% Tetrasodium EDTA to Prevent Central Venous Access Device-Associated Complications: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

在6家加拿大医院ICU开展实用性三盲多中心整群随机交叉试验,纳入1468例成人患者,比较4%四钠EDTA与对照封管液。

要点

  • 4% t-EDTA封管可降低ICU成人CVAD相关复合结局发生率。
  • 复合结局降低主要由需阿替普酶处理的导管闭塞减少驱动。
  • 导管相关血流感染和因闭塞拔管率未显示显著差异。

核心结论

  • 与对照封管液相比,4% t-EDTA封管液可降低ICU成人患者CVAD相关血流感染、需阿替普酶使用的导管闭塞及因闭塞拔管的复合结局发生率。

研究设计与样本

  • 实用性、三盲、多中心、整群随机交叉试验,在6家加拿大医院(3家社区医院和3家学术中心)ICU开展。
  • 纳入1574例合格患者中1468例进行分析(平均年龄60岁,SD 16.0;女性37.7%),t-EDTA组696例,对照组772例。
  • ICU随机使用含2.5 mL t-EDTA或对照封管液(生理盐水或4%枸橼酸盐用于血液透析管路)的预填充盲法注射器,3.5个月后经过1个月随访期交叉至对侧组再干预3.5个月并随访1个月。
  • 首例患者入组2022年3月22日,末次随访2024年9月25日。

主要发现

  • 主要复合结局发生率:t-EDTA组13.1/1000导管日(74起事件),对照组19.9/1000导管日(126起事件)。
  • 主要结局3个组分中,仅需使用阿替普酶的CVAD闭塞次要结局在组间有显著差异,t-EDTA组低于对照组(66 vs 112;发生率11.67 vs 17.73/1000导管日;率比0.66;95%CI 0.46-0.96)。

临床怎么用

  • 对ICU内留置CVAD且至少1个腔未使用的成人患者,可考虑使用4% t-EDTA封管液以减少CVAD相关复合并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Use of central venous access devices (CVADs) can result in catheter-associated bloodstream infection, catheter occlusion, and catheter-related venous thrombosis. EDTA is a potent anticoagulant, antimicrobial, and antibiofilm agent that can be instilled into inactive CVAD ports as a locking fluid to decrease the risk of infection and maintain patency. OBJECTIVE: To determine whether a 4% tetrasodium EDTA (t-EDTA) locking fluid reduces CVAD-associated infections, occlusions, and thrombolytic use in adults treated in an intensive care unit (ICU). DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, triple-blind, multicenter, cluster-randomized crossover trial including patients older than 18 years in the ICU with a CVAD in place and at least 1 lumen not in use. The trial was conducted in 6 Canadian hospitals (3 community hospitals and 3 academic centers). The first patient was enrolled on March 22, 2022, and the date of last follow-up occurred on September 25, 2024. INTERVENTIONS: The ICUs were randomized to use prefilled, identical, masked syringes containing 2.5 mL of t-EDTA (intervention) or control locking fluid (saline or 4% citrate for hemodialysis lines) for all trial participants over a 3.5-month period. After a 1-month follow-up period, ICUs crossed over to the opposing treatment group for another 3.5 months, with a subsequent 1-month follow-up. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite incidence rate of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and/or catheter removal due to occlusion. Three of the 8 prespecified secondary outcomes included incidence rates of each component of the primary outcome separately. RESULTS: Of the 1574 eligible patients, 1468 (mean age, 60 [SD, 16.0] years; 37.7% female) were included in the analysis (696 receiving t-EDTA and 772 receiving control). The incidence rate of primary outcome events was 13.1 per 1000 catheter-days (74 events) in the t-EDTA group vs 19.9 per 1000 catheter-days (126 events) in the control group. In adjusted multivariate analysis, the incidence rate of the composite outcome was lower among patients receiving t-EDTA vs control (rate ratio, 0.68; 95% CI, 0.47-0.96; P = .03). Among the 3 components of the primary outcome, only the secondary outcome of CVAD occlusion requiring administration of alteplase significantly differed between the groups, with lower rates in the t-EDTA group vs control (66 vs 112; incidence rate, 11.67 and 17.73 per 1000 catheter-days, respectively; rate ratio, 0.66; 95% CI, 0.46-0.96). CONCLUSIONS AND RELEVANCE: Compared with control locking solution, use of 4% t-EDTA locking solution for CVADs reduced the incidence of a composite outcome of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and catheter removal due to occlusion among adult patients in the ICU. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04548713.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ornowska M, Wittmann J, Blitz S, et al. 4% Tetrasodium EDTA to Prevent Central Venous Access Device-Associated Complications: A Randomized Clinical Trial. JAMA. 2026. PMID: 42150112. doi:10.1001/jama.2026.6025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。